ERBB2 and breast cancer: Over the last decade, with the arrival of HER‐2 targeted drugs, there has been a significant survival benefit for HER2‐positive locally recurrent or metastatic BC (mBC) patients in clinical trials, regardless of the HR status.3, 4, 5